CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Identifying the cheapest index funds for IRAs involves weighing costs against expected returns and risk. Learn practical benchmarking steps here.
22,746 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Open-source AI is drawing strong backing from investors and consumers alike. Hugging Face cofounder Thomas Wolf argue...
A major reinsurance renewal helped Lemonade rewrite its profit picture, sending LMND higher in a short week. Here’s w...
Palantir surging in July shines a contrast with Google’s cloud-driven growth. Both giants report strong quarters, but...
SpaceX's $7.7 billion AI infrastructure push in Q1 2026 marks a dramatic shift from traditional rocket business to da...
Stock splits grab headlines, but the real question for investors is whether the move changes the investment case. Thi...
Two AI-focused names have pulled back recently, but their paths diverge. This guide breaks down why palantir sandisk ...
When the market tumbles, smart investors lean into durable industrials. This guide highlights two robust picks and a ...
Federal Reserve Governor Michael S. Barr outlined three AI-driven labor-market futures, including a worst-case jobles...
Stock moves can be as signaling as they are financial. This article breaks down the factors behind etsy stock popped ...
As AI and data demand surge, investors eye NuScale Power and the small modular reactor trend. Can nuscale power next ...
Investors woke up to a jump in Micron shares after a period of volatility. This article breaks down the catalysts, th...